Sections

Home / India News / Sun Pharma to conduct clinical trial of pancreatitis drug in Covid-19 patients

Sun Pharma to conduct clinical trial of pancreatitis drug in Covid-19 patients

The University of Tokyo had announced plans for a trial of nafamostat and camostat mesilate, a related drug, starting as early as April 2020.

Updated: May 29, 2020 15:48 IST

By Reuters, Reuters

The University of Tokyo had announced plans for a trial of nafamostat and camostat mesilate, a related drug, starting as early as April 2020. (Photo by Himanshu Vyas/ Hindustan Times)

Drugmaker Sun Pharmaceutical Industries Ltd said on Friday that it received Indian regulatory approval to start clinical trials of pancreatitis drug nafamostat mesilate in COVID-19 patients.

“Nafamostat (has been) identified as a potential candidate for COVID-19 patients by scientists at University of Tokyo and Leibniz Institute for Primate Research, Germany,” the company said in a statement https://reut.rs/2BdSD4o.

The University of Tokyo had announced plans for a trial of nafamostat and camostat mesilate, a related drug, starting as early as April 2020.

tags

SCROLL FOR MORE NEWS
This site uses cookies

This site and its partners use technology such as cookies to personalize content and ads and analyse traffic. By using this site you agree to its privacy policy. You can change your mind and revisit your choices at anytime in future.